Merger

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

A deep dive into the valuation impasse that scuttled a major oil merger, and what the fallout means for Parex, GeoPark, and Latin American energy M&A.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

An unsolicited bid from Paramount Skydance challenges Netflix's deal for WBD, sparking a high-stakes war for Hollywood's most iconic content library.

Beyond insurance, Sammons Financial Group is building a holistic financial services model. What does this strategic pivot mean for clients and the industry?

A hedge fund's subtle move in Unite Group offers a rare glimpse into the high-stakes strategy behind the UK's student housing consolidation boom.

Arkansas-based Home BancShares is buying its way into Tennessee's booming economy. We dissect the 'triple accretive' deal to acquire Mountain Commerce.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

TotalEnergies is creating the UK's largest independent oil producer. A bold bet on fossil fuel efficiency or a contradiction to its green energy goals?

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

A PE firm's operational overhaul of a corporate carve-out leads to a strategic sale, highlighting the consolidation and tech trends reshaping security.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.